title: Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
abstract: OBJECTIVE
  To determine the effect of IV methylprednisolone (IVMP) on brain fraction volume (BFV), contrast-enhancing (CE) lesions, and white matter lesion load (WMLL) in patients with relapsing-remitting MS treated for acute exacerbations.
  
  
  BACKGROUND
  MRI metrics of MS disease activity are being used as outcome measures in early phase treatment trials, however the short-term effects of IVMP treatment on cerebral atrophy are unknown.
  
  
  METHODS
  Serial monthly MRI were performed in 26 patients enrolled in a baseline vs treatment trial with interferon beta-1b (IFNbeta-1b) who were followed for 3 months before and after IVMP. All 26 patients were evaluated while receiving IFNbeta-1b, and 12 patients were also studied during the baseline stage of the trial (NHx). Acute exacerbations were treated with IVMP (1 g/d) for 3 to 5 days. Precontrast and postcontrast T1-weighted and proton density T2-weighted fast spin-echo images were analyzed.
  
  
  RESULTS
  Fifty-six acute exacerbations were evaluated. For the 3 months before IVMP, there was no difference in WMLL or BFV compared to month IVMP was administered. There was a significant decrease in BFV at month 1 after IVMP in the IFNbeta-1b and NHx groups. Compared to the month IVMP was administered, there was a difference in the CE lesions for months -3 and -1 prior (p < 0.039) in NHx patients. Following IVMP, CE lesions decreased (p < 0.0004) for months 1, 2, and 3 in both groups, but there was no effect on WMLL.
  
  
  CONCLUSIONS
  BFV and CE lesions were significantly decreased for 1 month (BFV) and 3 months (CE lesions) following IVMP. Therefore, MRI studies should be delayed by probably at least 2 months following IVMP to avoid a possible confounding steroid effect in a clinical trial.
authors.affiliation: Laboratory of Diagnostic Radiology Research, Clinical Center, NIH, Bethesda, MD 20892, USA.
authors.forename: A B
authors.initials: AB
authors.lastname: Rao
authors.forename: N
authors.initials: N
authors.lastname: Richert
authors.forename: T
authors.initials: T
authors.lastname: Howard
authors.forename: B K
authors.initials: BK
authors.lastname: Lewis
authors.forename: C N
authors.initials: CN
authors.lastname: Bash
authors.forename: H F
authors.initials: HF
authors.lastname: McFarland
authors.forename: J A
authors.initials: JA
authors.lastname: Frank
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001284:Atrophy; D001921:Brain / Q000473:pathology*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D000068576:Interferon beta-1b; D016899:Interferon-beta; D008775:Methylprednisolone; D000068556:Interferon beta-1a